---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-052707"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T22:10:54.669124+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics closes $5M second tranche of convertible note; grants CEO/CSO options

## Summary
- Second $5M tranche under SEPA with YA II PN (Yorkville) funded Dec 30, 2024; convertible note bears 0% interest (18% on default).
- Conversion price is lower of $2.84/share or 94% of 5-day VWAP (with floor). Matures Dec 20, 2025; extendable by the company.
- Company granted CEO Pete O'Heeron options for 406,339 shares and CSO Hamid Khoja options for 176,200 shares at $2.36/share.
- Options vest 1/4 on Dec 27, 2025, then monthly over 36 months; issued under 2022 Stock Plan.
- Net proceeds from the SEPA (up to $25M over 2 years) will be used for general corporate purposes.

## SEC filing metadata
- accession: 0001493152-24-052707
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224052707/0001493152-24-052707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224052707/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-052707
- JSON: https://secwatch.observer/filing/0001493152-24-052707.json
- Plain text: https://secwatch.observer/filing/0001493152-24-052707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.